Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.47 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12652607 | 0.91 | NR2F2 (0.54) | NPC1RAB9ASMN1; SMN2DNPH1ADORA3 | |
| SCHEMBL12567124 | 0.91 | ABL1 (0.49) | NPC1RAB9ASMN1; SMN2ADORA3SLC29A1 | |
| SCHEMBL20008035 | 0.86 | ABL1 (0.50) | NPC1RAB9ASMN1; SMN2ADORA3NR2F2 | |
| SCHEMBL12567224 | 0.85 | ADORA3 (0.44) | NPC1RAB9ASMN1; SMN2ADORA3TSHR | |
| SCHEMBL12652414 | 0.84 | UBA6 (0.47) | NR2F2 | |
| SCHEMBL13467655 | 0.84 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2ADORA3TP53 | |
| SCHEMBL12567198 | 0.84 | ATG7 (0.46) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17875220 | 0.83 | SLC29A1 (0.60) | NPC1RAB9ASMN1; SMN2DNPH1ADORA3 | |
| SCHEMBL1796246 | 0.83 | SLC29A1 (0.60) | NPC1RAB9ASMN1; SMN2DNPH1ADORA3 | |
| SCHEMBL18630490 | 0.83 | P2RY12 (0.53) | ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7951810-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | NPC1 3774/4885RAB9A 2706/4885SMN1; SMN2 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.